Regeneron Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited enter a 50/50 collaboration to develop next-generation radiopharmaceutical therapies, with $40 million upfront and up to $2.1 billion in milestones.
Written By: Pharmacally Medical News Desk
Regeneron Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited have entered a strategic collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies, with both companies sharing development costs and global profits equally. The agreement combines Regeneron’s antibody discovery and oncology development capabilities with Telix’s radiopharmaceutical development, manufacturing, and supply infrastructure.
The collaboration will initially focus on four therapeutic programs targeting solid tumors using antibodies from Regeneron’s VelocImmune® platform. Regeneron also has the option to expand the partnership to include four additional programs with further upfront payments. In parallel, the companies plan to co-develop companion radio-diagnostic agents to support patient selection and monitor treatment response.
Under the financial terms, Telix will receive $40 million upfront for access to its radiopharmaceutical manufacturing platform for the initial programs. The companies will share global commercialization costs and profits on a 50/50 basis, and Telix may co-promote certain products. If Telix chooses not to co-fund a program, it will instead be eligible for up to $535 million in development and commercial milestone payments per program, along with low double-digit royalties on future net sales. Across programs, total potential milestone payments could reach up to $2.1 billion.
The partnership also includes joint development of diagnostic assets, with Telix leading commercialization while Regeneron receives a share of profits.
John Lin M.D., Ph.D., Senior Vice President of Oncology & Antibody Technology Research at Regeneron said targeted radiopharmaceuticals represent an emerging modality in oncology and expand Regeneron’s therapeutic toolkit, which already includes monoclonal antibodies, bispecifics, and cell therapies. He noted the collaboration aims to develop new treatment options for patients with difficult-to-treat cancers.
Israel Lowy M.D., Ph.D., Senior Vice President, Clinical Development Unit Head, Oncology at Regeneron added that Telix’s radiopharmaceutical expertise complements Regeneron’s antibody technologies. He highlighted the potential to evaluate these agents both as standalone therapies and in combination with immunotherapy approaches, particularly in areas of high unmet need such as lung cancer.
Christian Behrenbruch D.Phil., Managing Director and Group CEO at Telix stated that the collaboration brings together complementary capabilities and is intended to advance biologics-based radiopharmaceuticals designed for precision oncology applications in hard-to-treat tumors.
Reference
13 Aprill 2026, Telix and Regeneron Announce Strategic Radiopharma Collaboration – Telix Pharmaceuticals
13 April 2026, Regeneron and Telix Announce Strategic Radiopharma Collaboration | Regeneron Pharmaceuticals Inc.
